Compositions and methods of inhibiting gene expression in a lung
US-2015368648-A1 · Dec 24, 2015 · US
Compositions and methods for siRNA inhibition of angiogenesis
US8946403B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8946403-B2 |
| Application number | US-201314042040-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 30, 2013 |
| Priority date | Jul 24, 2002 |
| Publication date | Feb 3, 2015 |
| Grant date | Feb 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs.
First claim
Opening claim text (preview).
We claim: 1. An isolated dsRNA consisting of a 19 to 25 nucleotide sense RNA strand and a 19 to 25 nucleotide antisense RNA strand, wherein the sense and the antisense RNA strands form an RNA duplex, and wherein the antisense RNA strand consists of a nucleotide sequence that hybridizes to SEQ ID NOs: 20 or 52. 2. The dsRNA of claim 1 , wherein the antisense RNA strand consists of a nucleotide sequence that hybridizes to SEQ ID NOs: 20 and 52.…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8946403B2 cover?
- RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering…
- Who is the assignee on this patent?
- Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1136. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).